Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial
The TACSI trial (ClinicalTrials.gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome. The TACSI trial is an investor-initiated pragmatic, prospective, multinational, multicenter, open-
